Table 4.
Relative changes in serum testosterone levels
| Baseline to end of RT | Baseline to 3 months post-RT | |||||
|---|---|---|---|---|---|---|
| All (n = 447) |
WPRT (n = 386) |
PORT (n = 61) |
All (n = 371) |
WPRT (n = 320) |
PORT (n = 51) |
|
| Minimum | −96.5% | −96.5% | −53.4% | −96.8% | −96.8% | −69.7% |
| 5th percentile | −51.1% | −52.6% | −43.5% | −46.4% | −46.6% | −45.1% |
| Q1 | −27.3% | −27.8% | −14.4% | −25.8% | −26.1% | −24.0% |
| Median | −9.2% | −10.0% | −2.5% | −9.3% | −9.1% | −13.5% |
| Q3 | 12.8% | 13.0% | 12.4% | 9.5% | 13.6% | 4.8% |
| 95th percentile | 59.1% | 59.1% | 53.0% | 53.1% | 57.9% | 22.2% |
| Maximum | 173.1% | 173.1% | 78.6% | 179.2% | 179.2% | 28.6% |
| P-valuea | < .001 | < .001 | .354 | < .001 | .001 | .001 |
| P valueb | .172 | .348 | ||||
Q1, first quartile; Q3, third quartile; PORT, prostate-only radiation therapy; RT, radiation therapy; WPRT, whole-pelvis radiation therapy.
a
P-value from Wilcoxon Signed-Rank test comparing to 0.
b
P-value comparing WPRT vs. PORT from Wilcoxon test.